Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results [Yahoo! Finance]
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: Yahoo! Finance
preclinical pipeline, including additional data from novel delivery capsid, STAC-BBB, that demonstrated industry-leading blood-brain barrier (BBB) penetration in non-human primates (NHPs) following intravenous administration. Announced discovery of novel next-generation modular integrase (MINT) platform that allows targeting of a serine recombinase engineered to enable large-scale genome editing. Completed dosing in Phase 1/2 STAAR study of isaralgagene civaparvovec for Fabry disease and engaged in active discussions with potential Fabry collaboration partners. Pfizer anticipates biologics license application (BLA) and marketing authorization application (MAA) submissions for Hemophilia A collaboration in early 2025 if mid-2024 pivotal readout is supportive. Raised approximately $24 million in gross proceeds from a registered direct offering with institutional investors. RICHMOND, Calif., May 09, 2024 BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medi
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsBusiness Wire
SGMO
Earnings
- 5/9/24 - Miss
SGMO
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/30/24 - Form 8-K
- SGMO's page on the SEC website